ArticleAdvanced sensor research2025
Complementary cost-effective electrochemical platforms for point-of-use biosensing.
Article in Advanced sensor research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The COVID-19 pandemic has illustrated the urgent need for rapid and affordable point-of-use diagnostics. Electrochemical biosensors are useful for such applications because they enable quantitative readout and show drastically improved sensitivity compared to prevalent lateral flow technologies. However, to-date, the poor quality of commercially-available, mass-produced electrodes has prohibited the scaled production and commercialization of such biosensors beyond glucose sensing. We previously developed low-cost gold leaf electrodes that can be fabricated with no specialized equipment at the point-of-use. These electrodes are more effective for biosensing than prevalent commercially-available systems. Yet, their manual fabrication can be tedious and is not scalable in its current form. Here, we evaluate the performance of mass-produced gold electrodes generated using roll-to-roll manufacturing, offering the potential to scale production. Upon comparison of these electrodes with our gold leaf, we find that these electrodes are high quality, equivalent to our gold leaf electrodes, and support biosensing applications through the detection of both DNase I and BtsI-v2 activity with comparable performance. These results demonstrate the role of complementary technologies to achieve point-of-use sensing by enabling flexibility between mass-produced manufacture and on-site production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.